Seer, Inc. (SEER)

NASDAQ: SEER · IEX Real-Time Price · USD
2.29
+0.02 (0.88%)
Sep 22, 2023, 4:00 PM EDT - Market closed
0.88%
Market Cap 146.42M
Revenue (ttm) 16.62M
Net Income (ttm) -93.90M
Shares Out 63.94M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 220,543
Open 2.28
Previous Close 2.27
Day's Range 2.26 - 2.32
52-Week Range 2.25 - 8.78
Beta 1.42
Analysts Sell
Price Target 8.25 (+260.26%)
Earnings Date Nov 7, 2023

About SEER

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and b... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2020
Employees 164
Stock Exchange NASDAQ
Ticker Symbol SEER
Full Company Profile

Financial Performance

In 2022, Seer, Inc.'s revenue was $15.49 million, an increase of 134.14% compared to the previous year's $6.62 million. Losses were -$92.97 million, 30.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SEER stock is "Sell." The 12-month stock price forecast is $8.25, which is an increase of 260.26% from the latest price.

Price Target
$8.25
(260.26% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Seer to Participate in Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management...

15 days ago - GlobeNewsWire

Seer Reports Second Quarter 2023 Financial Results

Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies

6 weeks ago - GlobeNewsWire

Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference

REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...

2 months ago - GlobeNewsWire

Seer to Report Second Quarter 2023 Financial Results on August 8, 2023

REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...

2 months ago - GlobeNewsWire

Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center

Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific commu...

3 months ago - GlobeNewsWire

Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies

Seer's Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale Seer's Proteograph X...

4 months ago - GlobeNewsWire

Seer Reports First Quarter 2023 Financial Results

Grew revenue 22% year-over-year with continued growth in installed base and an increasing number of customer presentations and publications REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Seer,...

4 months ago - GlobeNewsWire

Seer to Report First Quarter 2023 Financial Results on May 9, 2023

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will repor...

5 months ago - GlobeNewsWire

Seer's Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression

Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers Peptide-level insights from deep, un...

6 months ago - GlobeNewsWire

Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook

Grew revenue 134% and increased instruments shipped 129% year over year Grew revenue 134% and increased instruments shipped 129% year over year

7 months ago - GlobeNewsWire

Seer to Present at the Cowen 43rd Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wi...

7 months ago - GlobeNewsWire

Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report...

8 months ago - GlobeNewsWire

Seer to Present at the J.P. Morgan 41st Annual Health Care Conference

REDWOOD CITY, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wi...

9 months ago - GlobeNewsWire

DISCOVERY LIFE SCIENCES LAUNCHES WORLD-CLASS PROTEOMIC SERVICES DIVISION SUPPORTED BY LEADING TECHNOLOGY PARTNERS

Creates a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis to support drug and diagnostic development HUNTSVILLE, Ala. , Dec. 14, 2022 /PRN...

Other symbols: OLK
10 months ago - PRNewsWire

Seer's Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist

Annual award from The Scientist celebrates transformative products like Seer's Proteograph™ Product Suite, which make unbiased, at-scale proteomics accessible Annual award from The Scientist celebrate...

10 months ago - GlobeNewsWire

Seer Reports Third Quarter 2022 Financial Results

Proteograph utility is demonstrated as market interest continues to build with multiple studies underway Proteograph utility is demonstrated as market interest continues to build with multiple studies...

11 months ago - GlobeNewsWire

Seer to Report Third Quarter 2022 Financial Results on November 8, 2022

REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...

1 year ago - GlobeNewsWire

Seer to Participate in the Morgan Stanley Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wi...

1 year ago - GlobeNewsWire

Seer Announces Publication of Seminal Study Demonstrating the Power of Engineered Nano-Bio Interactions to Enable Deep Access to the Proteome

Published results highlight how the combination of proteomic methods, nanoengineering and machine learning enables the capture of thousands of proteins Published results highlight how the combination ...

1 year ago - GlobeNewsWire

Seer Reports Second Quarter 2022 Financial Results

Company launches novel proteogenomics workflow with the Proteograph™ Analysis Suite 2.0, further demonstrates the power of its technology with new customer data, and advances key partnerships Company ...

1 year ago - GlobeNewsWire

Seer Launches First-of-its-kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograph™ Analysis Suite 2.0

Scalable, high-resolution, sample-specific analysis brings genomics and proteomics together to enable novel biological insights with the click of a button Scalable, high-resolution, sample-specific an...

1 year ago - GlobeNewsWire

Seer to Report Second Quarter 2022 Financial Results on August 9, 2022

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report finan...

1 year ago - GlobeNewsWire

Seer Reports First Quarter 2022 Financial Results

Demonstrated solid commercial traction with continued robust interest in the Proteograph Product Suite Demonstrated solid commercial traction with continued robust interest in the Proteograph Product ...

1 year ago - GlobeNewsWire

Seer to Present at the BofA Securities 2022 Healthcare Conference

REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company w...

1 year ago - GlobeNewsWire

Seer to Report First Quarter Financial Results on May 4, 2022

REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...

1 year ago - GlobeNewsWire